Evidence map›Paper›PMID 40376683›Full record

ArticleNeuro-oncology advances

Effects of craniectomy defect on tumor-treating fields.

Edwin Lok, Bryant Chang, Rafael Vega, Monika Haack, Eric T Wong

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Tantalum-Based Nanomaterials: From Properties to Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Edwin LokDivision of Hematology/Oncology, Department of Medicine, Brown University Health & Rhode Island Hospital, Providence, Rhode Island, USA.
Bryant ChangDivision of Neurosurgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Rafael VegaDivision of Neurosurgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Monika HaackDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Eric T WongDepartment of Neurology, Medicine, Neurosurgery & Radiation Oncology, Brown University Health & Rhode Island Hospital, Providence, Rhode Island, USA.ORCID https://orcid.org/0000-0001-7112-6207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tumor-treating fields (TTFields) are alternating electric fields approved for the treatment of glioblastoma. They must penetrate through the skull to reach the gross tumor volume (GTV) in the brain. Since the skull is an attenuator of electric fields, removal of a section of cortical bone by craniectomy may facilitate the delivery of TTFields into the GTV. Methods: We identified a glioblastoma patient who underwent craniectomy for evacuation of a subdural empyema. The patient subsequently received standard adjuvant treatment with TTFields plus temozolomide without replacement of the skull defect. Post-acquisition magnetic resonance imaging datasets were obtained from this index patient and 2 others for virtual craniectomy analysis. After anatomic delineation, a 3-dimensional finite element mesh was generated and then solved for the distribution of applied electric fields, rate of energy deposition, and current density at the GTV. Results: The geometry of craniectomy defect alone, with or without burr holes, did not alter TTFields delivery to GTV. Biomaterials filling the defect could significantly influence electric field penetration, particularly when they are highly conductive at 10 S/m or 7.76 × 10 Conclusions: Craniectomy, biomaterials filling the defect, and the ratio of GTV relative to defect size may interact in a combinatorial fashion in modulating TTFields penetration into the brain. These findings are clinically relevant for personalized TTFields treatment.

Indexed as

craniotomydefectglioblastomatumor-treating fields

Identifiers

PMID40376683
PMCPMC12080538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.